LSX 2020: Medtronic, J&J And Olympus Map Their M&A Outlook
At the LSX World Congress in London, leaders from Medtronic, Johnson & Johnson and Olympus discussed the evolving medtech mergers and acquisitions landscape, the big opportunity in robotic surgery and the impacts on innovation of the forthcoming EU Medical Device Regulation.
You may also be interested in...
The EU Medical Device Regulation threatens the viability of many premarket innovators and SMEs in the UK, and across Europe. Eithne Lee, of ISO Life Sciences global consultancy, explains how the new requirements come as a shock for many small companies, how many are ill-prepared and how the cost of compliance relative to turnover may be too high. This is part one of a two-part article.
The company’s leadership discussed its recent investments in robotic surgery technology during Johnson & Johnson’s 2019 fourth-quarter earnings call on 22 January. The company will provide more information on its robotic surgery platforms at its investors meeting in May in New York.
Market Brief: Robotic Surgery Systems Market Will Reach $9.7Bn By 2023; Driven By Innovation, Procedure Volume Growth And Access To Emerging Markets
The global market for robotic surgery systems is expected to grow at a CAGR of 16%, reaching $9.7bn by 2023, driven by continued innovation, access to emerging markets and rising demand.